H.C. Wainwright assumed coverage of Eton Pharmaceuticals with a Buy rating and $9 price target. Eton is a commercial stage company that specializes in commercializing specialty products to treat pediatric ultra-rare diseases, the analyst tells investors in a research note. The firm expects Eton to achieve positive earnings in 2025 and finds the stock undervalued.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
- Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
- Eton Pharmaceuticals announces PDUFA date for ET-400 NDA
- Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)